Case Report

Syndrome of inappropriate secretion of antidiuretic hormone associated with angiotensin-converting enzyme inhibitor therapy in the perioperative period

Takashin Nakayama1, Hiroto Fujisaki2, Shintaro Hirai1, Ruri Kawauchi1, Kyohei Ogawa1, Ayaka Mitsui1, Keita Hirano1, Kazuo Isozumi1, Takayuki Takahashi2 and Satoru Komatsumoto1

Abstract

Introduction: Angiotensin-converting enzyme (ACE) inhibitors are one of the most commonly used medications for hypertension. Rarely, ACE inhibitors have the potential to cause a syndrome of inappropriate secretion of antidiuretic hormone (SIADH).

Case presentation: A 70-year-old woman with > 10 years ACE inhibitor therapy with normonatremia suddenly developed severe SIADH when she took a liquid diet in the uneventful perioperative period, with hemodynamic stability and no surgical complications. She promptly recovered from SIADH subsequent to discontinuing the ACE inhibitor and free water load from the liquid diet contributed to hyponatremia in our patient.

Conclusion: Patients treated with an ACE inhibitor can latently experience inappropriate secretion of antidiuretic hormone, and rapidly develop severe hyponatremia together with additional factors affecting water or salt homeostasis regardless of the length of the administration duration. Clinicians should monitor serum sodium levels in such patients not only just after the initiation of ACE inhibitors but also upon the appearance of those factors.

Keywords

Syndrome of inappropriate secretion of antidiuretic hormone, hyponatremia, angiotensin-converting enzyme inhibitor, lisinopril, perioperative

Date received: 6 November 2018; accepted: 29 January 2019

Introduction

Many hypertension guidelines mention angiotensin-converting enzyme (ACE) inhibitors as key medications for treating hypertension. However, there are scant reports on ACE inhibitor use and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH), in which patients develop SIADH mostly within 1 year after the start of treatment with ACE inhibitors. Because severe hyponatremia can cause irreversible brain damage and even death, early detection and appropriate treatment are crucial. Here, we report the case of a woman who had been taking lisinopril for > 10 years and developed severe hyponatremia during the perioperative period. Early treatment produced a favorable outcome.

Case presentation

A 70-year-old woman with a history of hypertension who had taken lisinopril for > 10 years was admitted to our hospital for a pancreatoduodenectomy due to intraductal papillary mucinous carcinoma. Her blood pressure decreased to approximately 110 mm Hg (systolic) on postoperative day 1, and lisinopril was discontinued. She promptly recovered from SIADH subsequent to discontinuing the ACE inhibitor therapy and changing her diet. Therefore, it was assumed that excess antidiuretic hormone secretion due to an ACE inhibitor and free water load from the liquid diet contributed to hyponatremia in our patient.

Corresponding author:

Takashin Nakayama, Department of Internal Medicine, Ashikaga Red Cross Hospital, Japan

Department of Surgery, Ashikaga Red Cross Hospital, Japan

Email: takashin.nakayama@gmail.com
received approximately 40 ml/kg/day infusion volume a day, and her urinary volume had been > 1 ml/kg/h. On postoperative day 4, she was started on a liquid diet and the infusion was tapered. On postoperative day 5, the intraperitoneal drain tube was removed and no surgical complications, such as anastomotic leakage, bleeding or ileus, were noted. She resumed lisinopril (10 mg) on postoperative day 7 after her blood pressure rose to approximately 150 mm Hg (systolic). However, she suddenly developed hiccups and fatigue 4 days later. Her blood pressure was 142/79 mm Hg, her heart rate was 74 beats/min and her temperature was 36.2°C. The lung fields were clear to auscultation and neurological examination was symmetrical. She had no obvious symptoms of dehydration or overhydration. After taking lisinopril for 4 days, her serum sodium level decreased from 137 to 115 mEq/L (Figure 1). Other laboratory values included serum potassium 4.8 mmol/L, blood urea nitrogen 8.3 mg/dL, serum creatinine 0.42 mg/dL, uric acid 0.8 mg/dL, glucose 164 mg/dL, serum sodium 147 mmol/L, urine potassium 28.6 mmol/L, serum osmolality 245 mOsm/kg and urine osmolality 478 mOsm/kg. Thyroid, adrenal and liver function tests were normal. Chest X-ray revealed a cardiothoracic ratio of 49% and sharp costophrenic angles. Echocardiography revealed an ejection fraction of 60%, inferior vena cava diameter during quiet expiration 10 mm and during quiet inspiration 4 mm, and no valvular heart disease. At this point, she was suspected of having SIADH associated with lisinopril. After discontinuing lisinopril for 2 days and changing from a postoperative to a general diet with hypertonic saline administration, her serum sodium level increased from 115 to 132 mmol/L and her urine sodium level decreased from 147 to 71 mmol/L. Moreover, her hiccups and fatigue, suspected to be due to hyponatremia, improved. Although she was started on losartan (25 mg), an angiotensin II receptor blocker (ARB), as a substitute for lisinopril on postoperative day 15, her serum sodium level was 141 mEq/L on postoperative day 30. Written informed consent for patient information to be published was provided by the patient.

Discussion

Our patient had been taking lisinopril (10 mg) for > 10 years without any side effects. After the operation, her urinary balance had been appropriate with hemodynamic stability, no surgical complications were noted and the wound pain also disappeared on postoperative day 6. These findings indicated that the postoperative process was uneventful. Although she received a postoperative diet with normonatremia for several days, her serum sodium level decreased rapidly 4 days after restarting lisinopril (10 mg) and normalized 2 days after discontinuing it. Therefore, it is possible that the latent inappropriate secretion of antidiuretic hormone (ADH) due to lisinopril became evident with the increased water load from the postoperative diet.

Rarely, ACE inhibitors can cause SIADH, but the mechanism is unclear. We searched PubMed for the key words “ACE inhibitor, SIADH” and “ACE inhibitor, hyponatremia,” and extracted 14 case reports in reference to the Saeed et al. diagnostic criteria for SIADH (Table 1).3–17 Although those criteria include no recent use of diuretic agents, we believe that hyponatremia, which is often...
multifaceted, can result from both the use of diuretic agents and inappropriate ADH secretion. Consequently, we also extracted reports on patients undergoing diuretic therapy for hyponatremia to collect as much research as possible regarding the association between ACE inhibitors and ADH hypersecretion. However, only 7 patients did not receive diuretic agents, including our patient, whose hyponatremia was probably mostly due to the ACE inhibitor. We believe that ACE inhibitors are less frequently the primary cause of hyponatremia due to inappropriate ADH secretion than previously thought.

The duration of ACE inhibitor administration varied widely, from 2 days to 5 years. Notably, almost all patients developed hyponatremia within 1 month of starting an ACE inhibitor, or based on the appearance of other factors affecting water or salt homeostasis, including exacerbation of respiratory or heart disease, adjustment of drugs affecting their homeostasis and a load of free water. This suggests that the additive factors first actualize inappropriate secretion of ADH by the ACE inhibitor. In fact, although our patient had been taking the ACE inhibitor for > 10 years with normonatremia, she suddenly developed SIADH with a liquid diet, leading to a load of free water. Regardless of the duration of ACE inhibitor administration, ADH hypersecretion associated with ACE inhibitor therapy could be accompanied by the said factors affecting water or salt homeostasis.

The prognosis of ACE inhibitor-associated SIADH appears to be very good. All patients recovered from SIADH within 1 week of discontinuing ACE inhibitors and without any sequelae. In this context, the future management of hypertension remains controversial. Because two of four patients who relapsed when ACE inhibitors were reintroduced after cessation had improved their hyponatremia, we cannot recommend this approach. The mechanisms of action of calcium antagonists, alpha-1 antagonists and ACE inhibitors differ. To the best of our knowledge, an ARB has not induced SIADH, and a renin–angiotensin system inhibitor has the same effect as an ACE inhibitor. Consequently, we selected an ARB as an appropriate therapy for our patient, who had a high risk of developing SIADH.

| Reference (number) | Age (years)/sex | Past history | Serum sodium\(^1\) (mEq/L) | ACE inhibitor | Onset of hyponatremia | New factors affecting water or sodium homeostasis | Outcome |
|--------------------|----------------|--------------|-----------------------------|---------------|----------------------|-----------------------------------------------|---------|
| 4                  | 68/F           | HT           | Normal                      | Enalapril     | 4                   | Bendrofluimethiazide, Atenolol                  | Start of diuretics, Recovery |
| 5                  | 47/M           | DCM          | Not listed                  | Captopril     | 24                  | Furosemide                                    | Exacerbation of heart failure, Recovery |
| 6                  | 63/F           | HT           | 137                         | Lisinopril    | < 1                 | None                                          | None, Recovery |
| 7                  | 67/F           | HT, DM       | 141                         | Enalapril     | < 1                 | None                                          | None, Recovery |
| 8                  | 69/F           | HT, DM       | Not listed                  | Lisinopril    | 4                   | Atenolol, Amiloride, Thiazide                  | Start of diuretics, Recovery |
| 9                  | 66/M           | HT, IHD      | 132                         | Lisinopril    | < 1                 | None, Cerebral hemorrhage                      | Recovery |
| 10                 | 76/F           | HT           | 138                         | Lisinopril    | 66                  | Metoprolol, Diclofenac                        | Increase of lisinopril, Recovery |
| 11                 | 85/F           | HT, IHD      | Not listed                  | Cilazapril    | < 1                 | None                                          | None, Recovery |
| 12                 | 60/M           | DCM          | 140                         | Enalapril     | < 1                 | Omeprazole                                    | Myocarditis, Recovery |
| 13                 | 74/F           | HT           | Not listed                  | Lisinopril    | < 18 (no follow-up)| None                                          | None, Recovery |
| 14                 | 76/F           | HT, AF, DM   | Normal                      | Ramipril      | < 1                 | Amiloride, Hydrochlorothiazide                 | None, Recovery |
| 15                 | 5/M            | HT\(^a\)     | 140                         | Enalapril     | < 1                 | None                                          | None, Recovery |
| 16                 | 6/M            | RCM          | 121                         | Cilazapril    | < 1                 | Azosemide, Trichlormethiazide                 | Exacerbation of heart failure, Recovery |
| 17                 | 78/F           | HT           | Normal                      | Lisinopril    | < 12                | Chlorthalidone                                | Start of diuretics, Recovery |
| Our case           | 71/F           | HT           | 137                         | Lisinopril    | 144                 | Lansoprazole                                  | Free water load in perioperative period, Recovery |

ACE: angiotensin-converting enzyme; AF: atrial fibrillation; DCM: dilated cardiomyopathy; DM: diabetes mellitus; F: female; HT: hypertension; IHD: ischemic heart disease; M: male; RCM: restrictive cardiomyopathy.

\(^1\)Serum sodium level before ACE inhibitor was added.

\(^a\)The patient suffered from unilateral renal hypertension.
alternative to an ACE inhibitor in the case of suspected SIADH associated with ACE inhibitor therapy, and our patient was normonatremic through postoperative day 30. Although it was necessary for our patient to consume a liquid diet with ARB therapy to adequately test this approach, she did not want to do so.

We still do not understand how ACE inhibitors induce SIADH. One possibility is that the ACE inhibitor blocks the conversion of angiotensin I to angiotensin II in the peripheral circulation, but not in the brain. Therefore, excess angiotensin I in the peripheral circulation enters the brain and is converted to angiotensin II, enhancing ADH secretion from the hypothalamus. Meanwhile, only five types of ACE inhibitor were reported to cause SIADH, and we have not found their pharmacokinetic properties to be different from other types of ACE inhibitors. In addition, we do not know why only a few patients are affected via this mechanism. Our search did not clearly reveal which patients are susceptible to ACE inhibitor-associated SIADH, but it appears to be more prevalent in women than in men (6 men and 10 women), and the majority of patients had a serum sodium level of < 140 mEq/L before starting the ACE inhibitor therapy. This might be related to the onset of ACE inhibitor-associated SIADH. It will be necessary to evaluate more cases that report an association between an ACE inhibitor and SIADH to better understand its underlying mechanisms and risk factors.

An ACE inhibitor can contribute to hyponatremia regardless of the length of the administration period. However, inappropriate secretion of ADH associated with ACE inhibitors may be overlooked in daily medical practice because, by themselves, ACE inhibitors induce symptomatic hyponatremia only very rarely. Clinicians should monitor serum sodium levels not only when an ACE inhibitor is introduced, but also on the appearance of factors affecting water or salt homeostasis.

Declaration of Conflicting Interest
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iD
Takashin Nakayama  https://orcid.org/0000-0003-2498-2793

References
1. Kjeldsen S, Feldman RD, Lisheng L, et al. Updated national and international hypertension guidelines: A review of current recommendations. Drugs 2014; 74: 2033–2051.
2. Adrogué HJ and Madias NE. Hyponatremia. N Engl J Med 2000; 342: 1581–1589.
3. Saced BO, Beaumont D, Handley GH, et al. Severe hyponatraemia: Investigation and management in a district general hospital. J Clin Pathol 2002; 55: 893–896.
4. Collier JG and Webb DJ. Severe thiazide-induced hyponatraemia during treatment with enalapril. Postgrad Med J 1987; 63: 1105–1106.
5. Inoue S, Hasegawa K, Nakamura T, et al. Severe hyponatremia associated with captopril therapy in dilated cardiomyopathy: A case report. Kokyū To Junkan 1989; 37: 1143–1146.
6. Subramanian D and Ayus JC. Case report: Severe symptomatic hyponatremia associated with lisinopril therapy. Am J Med Sci 1992; 303: 177–179.
7. González-Martínez H, Gaspard JJ and Espino DV. Hyponatremia due to enalapril in an elderly patient. A case report. Arch Fam Med 1993; 2: 791–793.
8. Castrillón JL, Mediavilla A, Méndez MA, et al. Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and enalapril. J Intern Med 1993; 233: 89–91.
9. Moussa NA, Osman AR and Yahya TM. Acute hyponatremic encephalopathy after a cerebrovascular accident. Am J Med Sci 1998; 316: 56–59.
10. Shaikh ZH, Taylor HC, Maroo PV, et al. Syndrome of inappropriate antidiuretic hormone secretion associated with lisinopril. Ann Pharmacother 2000; 34: 176–179.
11. Arinzon ZH, Lehrman YA and Fidelman ZG. Cilazapril-induced SIADH. J Am Geriatr Soc 2001; 49: 1735.
12. Izzedine H, Fardet L, Launay-Vacher V, et al. Angiotensin-converting enzyme inhibitor-induced syndrome of inappropriate secretion of antidiuretic hormone: Case report and review of the literature. Clin Pharmacol Ther 2002; 71: 503–507.
13. Isao N, Hideo N and Fujinori N. A case report of angiotensin-converting enzyme inhibitor induced hyponatremia and rhabdomyolysis. Jpn Soc Intensive Care Med 2006; 13: 263–264.
14. Arroyo DE, Soriano BA, Yuste VD, et al. Inappropriate antidiuretic hormone secretion syndrome associated with ramipril treatment. Farm Hosp 2010; 34: 154–155 (in Spanish).
15. Zaki SA, Bhongade S and Shanbag P. Enalapril-induced severe hyponatremia and altered sensorium in a child. Indian J Pharmacol 2011; 43: 605–606.
16. Murakami T, Horibata Y, Morimoto Y, et al. Syndrome of inappropriate secretion of antidiuretic hormone associated with angiotensin-converting enzyme inhibitor administration. Pediatr Cardiol 2013; 34: 1261–1263.
17. Prieto de PJM, Samnamed SN, Pérez FC, et al. Enalapril and inappropriate antidiuretic hormone secretion. Semergen 2013; 39: 400–401 (in Spanish).
18. Phillips MI. New evidence for brain angiotensin and its role in hypertension. Fed Proc 1983; 42: 2667–2672.
19. Ferner RE, Simpson SM, Rawlins MD, et al. Effect of intradermal bradykinin after inhibition of angiotensin converting enzyme. Br Med J 1987; 294: 1117–1120.
20. Hoyer J, Schulte KL and Lenz T. Clinical pharmacokinetics of angiotensin converting enzyme (ACE) inhibitors in renal failure. Clin Pharmacokin 1993; 24: 230–254.
21. Song JC and White CM. Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: An update. Clin Pharmacokinet 2002; 41: 207–224.